A tiny, EPFL-designed implantable device that can be positioned within the eye and controlled remotely may well revolutionize the treatment of glaucoma. The device should be through testing this year and on its way to the market in 2014 via Rheon Medical, an EPFL spin-off.
Glaucoma is the second leading cause of blindness globally, after cataracts. It is characterized by the presence of too much liquid between the cornea and the iris. This leads to a build-up of pressure within the eye, a situation that can destroy the optic nerve if it is not handled correctly.
Read more at: EPFL